Johnson & Johnson is the fourth Covid-19 vaccine candidate that has gone into the final stage of clinical trials.

Phase 3 testing for Johnson & Johnson will include 60,000 participants across 215 locations in the U.S. and other countries. Their number of participants is twice as much as AstraZeneca’s participants.

Paul Stoffels, J&J’s chief scientific officer told reporters that their vaccine appears to be well-tolerated, with symptoms such as fever resolving within 48 hours.

Results from the testing are not to be expected before at least two months. However US president Trump is putting pressure on faster work as he wants a vaccine done before the November 3rd election. However this is very hard for Johnson & Johnson to accomplish.

“These things don’t just happen overnight. What you’re seeing now is the result of the fruitful relationships that have been developed over literally several years,” the agency’s director, Dr. Anthony Fauci said.